Abiraterone acetate in castration-resistant prostate cancer

Roberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, Paola Gazzaniga, Enrico Cortesi

Research output: Contribution to journalArticle

Abstract

The palliative goal of the treatment of metastatic prostate cancer is to prolong survival and decrease cancer-related complications. Androgen ablation therapy is widely accepted as the initial treatment of choice; when the disease becomes resistant to castration-resistant prostate cancer (CRPC), docetaxel-based chemotherapy aids in prolonging overall survival and controlling disease-related symptoms. Until a few years ago, no drug had showed efficacy in docetaxel-resistant patients. Recently, cabazitaxel, a taxane family compound, has been shown to help prolong survival in patients previously treated with docetaxel, even if a high grade of myelotoxicity has been reported. Moreover, a better understanding of the biology of CRPC has demonstrated that prostate cancer proliferation is largely mediated through the androgen receptor, which could be reactivated by androgens produced by the adrenal glands. Abiraterone acetate is an orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17α-monooxygenase, a member of the cytochrome P450 family that catalyzes the 17α-hydroxylation of steroid intermediates involved in testosterone synthesis from the adrenal glands. This review focuses on abiraterone acetate, the first compound that, through the inhibition of adrenal gland production of testosterone, increases the overall survival in CRPC patients. The role of possible predictive biomarkers and future perspectives are also discussed.

Original languageEnglish
Pages (from-to)247-254
Number of pages8
JournalAnti-Cancer Drugs
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Adrenal Glands
Survival
Androgens
Testosterone
Steroid 17-alpha-Hydroxylase
Androgen Antagonists
Androgen Receptors
Hydroxylation
Palliative Care
Acetates
Salts
Biomarkers
Steroids
Abiraterone Acetate
Drug Therapy
Therapeutics
Pharmaceutical Preparations

Keywords

  • Abiraterone
  • Abiraterone acetate
  • Androgen
  • Castration-resistant prostate cancer
  • Chemotherapy
  • Circulating tumor cells
  • Clinical trials
  • Hormone therapy
  • Prostate cancer
  • Second line

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Abiraterone acetate in castration-resistant prostate cancer. / Iacovelli, Roberto; Palazzo, Antonella; Procopio, Giuseppe; Gazzaniga, Paola; Cortesi, Enrico.

In: Anti-Cancer Drugs, Vol. 23, No. 3, 03.2012, p. 247-254.

Research output: Contribution to journalArticle

@article{b3d08b638968467c88c4c22b7b66a2ad,
title = "Abiraterone acetate in castration-resistant prostate cancer",
abstract = "The palliative goal of the treatment of metastatic prostate cancer is to prolong survival and decrease cancer-related complications. Androgen ablation therapy is widely accepted as the initial treatment of choice; when the disease becomes resistant to castration-resistant prostate cancer (CRPC), docetaxel-based chemotherapy aids in prolonging overall survival and controlling disease-related symptoms. Until a few years ago, no drug had showed efficacy in docetaxel-resistant patients. Recently, cabazitaxel, a taxane family compound, has been shown to help prolong survival in patients previously treated with docetaxel, even if a high grade of myelotoxicity has been reported. Moreover, a better understanding of the biology of CRPC has demonstrated that prostate cancer proliferation is largely mediated through the androgen receptor, which could be reactivated by androgens produced by the adrenal glands. Abiraterone acetate is an orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17α-monooxygenase, a member of the cytochrome P450 family that catalyzes the 17α-hydroxylation of steroid intermediates involved in testosterone synthesis from the adrenal glands. This review focuses on abiraterone acetate, the first compound that, through the inhibition of adrenal gland production of testosterone, increases the overall survival in CRPC patients. The role of possible predictive biomarkers and future perspectives are also discussed.",
keywords = "Abiraterone, Abiraterone acetate, Androgen, Castration-resistant prostate cancer, Chemotherapy, Circulating tumor cells, Clinical trials, Hormone therapy, Prostate cancer, Second line",
author = "Roberto Iacovelli and Antonella Palazzo and Giuseppe Procopio and Paola Gazzaniga and Enrico Cortesi",
year = "2012",
month = "3",
doi = "10.1097/CAD.0b013e32834e696c",
language = "English",
volume = "23",
pages = "247--254",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Abiraterone acetate in castration-resistant prostate cancer

AU - Iacovelli, Roberto

AU - Palazzo, Antonella

AU - Procopio, Giuseppe

AU - Gazzaniga, Paola

AU - Cortesi, Enrico

PY - 2012/3

Y1 - 2012/3

N2 - The palliative goal of the treatment of metastatic prostate cancer is to prolong survival and decrease cancer-related complications. Androgen ablation therapy is widely accepted as the initial treatment of choice; when the disease becomes resistant to castration-resistant prostate cancer (CRPC), docetaxel-based chemotherapy aids in prolonging overall survival and controlling disease-related symptoms. Until a few years ago, no drug had showed efficacy in docetaxel-resistant patients. Recently, cabazitaxel, a taxane family compound, has been shown to help prolong survival in patients previously treated with docetaxel, even if a high grade of myelotoxicity has been reported. Moreover, a better understanding of the biology of CRPC has demonstrated that prostate cancer proliferation is largely mediated through the androgen receptor, which could be reactivated by androgens produced by the adrenal glands. Abiraterone acetate is an orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17α-monooxygenase, a member of the cytochrome P450 family that catalyzes the 17α-hydroxylation of steroid intermediates involved in testosterone synthesis from the adrenal glands. This review focuses on abiraterone acetate, the first compound that, through the inhibition of adrenal gland production of testosterone, increases the overall survival in CRPC patients. The role of possible predictive biomarkers and future perspectives are also discussed.

AB - The palliative goal of the treatment of metastatic prostate cancer is to prolong survival and decrease cancer-related complications. Androgen ablation therapy is widely accepted as the initial treatment of choice; when the disease becomes resistant to castration-resistant prostate cancer (CRPC), docetaxel-based chemotherapy aids in prolonging overall survival and controlling disease-related symptoms. Until a few years ago, no drug had showed efficacy in docetaxel-resistant patients. Recently, cabazitaxel, a taxane family compound, has been shown to help prolong survival in patients previously treated with docetaxel, even if a high grade of myelotoxicity has been reported. Moreover, a better understanding of the biology of CRPC has demonstrated that prostate cancer proliferation is largely mediated through the androgen receptor, which could be reactivated by androgens produced by the adrenal glands. Abiraterone acetate is an orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17α-monooxygenase, a member of the cytochrome P450 family that catalyzes the 17α-hydroxylation of steroid intermediates involved in testosterone synthesis from the adrenal glands. This review focuses on abiraterone acetate, the first compound that, through the inhibition of adrenal gland production of testosterone, increases the overall survival in CRPC patients. The role of possible predictive biomarkers and future perspectives are also discussed.

KW - Abiraterone

KW - Abiraterone acetate

KW - Androgen

KW - Castration-resistant prostate cancer

KW - Chemotherapy

KW - Circulating tumor cells

KW - Clinical trials

KW - Hormone therapy

KW - Prostate cancer

KW - Second line

UR - http://www.scopus.com/inward/record.url?scp=84858291043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858291043&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32834e696c

DO - 10.1097/CAD.0b013e32834e696c

M3 - Article

C2 - 22123334

AN - SCOPUS:84858291043

VL - 23

SP - 247

EP - 254

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -